[go: up one dir, main page]

HN2010000930A - Granulacion en humedo que utiliza un agente secuestrante de agua - Google Patents

Granulacion en humedo que utiliza un agente secuestrante de agua

Info

Publication number
HN2010000930A
HN2010000930A HN2010000930A HN2010000930A HN2010000930A HN 2010000930 A HN2010000930 A HN 2010000930A HN 2010000930 A HN2010000930 A HN 2010000930A HN 2010000930 A HN2010000930 A HN 2010000930A HN 2010000930 A HN2010000930 A HN 2010000930A
Authority
HN
Honduras
Prior art keywords
wet granulation
sequencing agent
granulation used
water
water sequencing
Prior art date
Application number
HN2010000930A
Other languages
English (en)
Inventor
Sun Thomas
Lo Ray
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40623940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2010000930(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of HN2010000930A publication Critical patent/HN2010000930A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCIONSE DESCRIBEN TABLETAS QUE COMPRENDEN FORMULACIONES ESTABLES HIDROLITICAMENTE DE SAL DESODICA DE (6-(5-FLUOR-2(3,4,5-TRIMETXIFENILAMINO)PIRIMIDIN-4-ILAMINO)-2,2-DIMETIL-3OXO-2H-PIRIDO(3,2-b)(1,4)OXAZIN-4(3H)-IL)METIL FOSFATO 1) PREPARADO POR UN PROCESO DE GRANULACION EN HUMEDO.
HN2010000930A 2007-11-07 2010-05-06 Granulacion en humedo que utiliza un agente secuestrante de agua HN2010000930A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98623707P 2007-11-07 2007-11-07

Publications (1)

Publication Number Publication Date
HN2010000930A true HN2010000930A (es) 2012-11-12

Family

ID=40623940

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010000930A HN2010000930A (es) 2007-11-07 2010-05-06 Granulacion en humedo que utiliza un agente secuestrante de agua

Country Status (34)

Country Link
US (3) US8263122B2 (es)
EP (1) EP2217241B1 (es)
JP (1) JP5567487B2 (es)
KR (2) KR101663838B1 (es)
CN (1) CN101998857A (es)
AU (1) AU2008323938B2 (es)
BR (1) BRPI0820389A2 (es)
CA (1) CA2704474C (es)
CO (1) CO6280491A2 (es)
CR (1) CR11476A (es)
CU (1) CU23915B1 (es)
CY (1) CY1122163T1 (es)
DK (1) DK2217241T3 (es)
DO (1) DOP2010000136A (es)
EA (1) EA020210B1 (es)
EC (1) ECSP10010233A (es)
ES (1) ES2672519T3 (es)
HN (1) HN2010000930A (es)
HR (1) HRP20181174T1 (es)
HU (1) HUE039193T2 (es)
IL (1) IL205204A (es)
LT (1) LT2217241T (es)
MX (1) MX2010004733A (es)
MY (1) MY169761A (es)
NI (1) NI201000078A (es)
NZ (1) NZ585913A (es)
PL (1) PL2217241T3 (es)
PT (1) PT2217241T (es)
RS (1) RS57525B1 (es)
SG (1) SG185961A1 (es)
SI (1) SI2217241T1 (es)
TR (1) TR201807879T4 (es)
UA (1) UA102825C2 (es)
WO (1) WO2009061909A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080223392A1 (en) * 2007-03-14 2008-09-18 L'oreal Process for relaxing or straightening hair
GB0814688D0 (en) 2008-08-12 2008-09-17 Knauf Insulation Thermal insulation product
AR079409A1 (es) * 2009-09-07 2012-01-25 Mukhopadhyay Debashis Preparaciones antihelminticas granuladas y sistemas de suninistros
CA2790199A1 (en) * 2010-02-24 2011-09-01 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
SI2736487T2 (sl) * 2011-07-28 2025-06-30 Rigel Pharmaceuticals, Inc. Nove formulacije (trimetoksifenilamino)pirimidinila
US20180296579A1 (en) 2015-04-24 2018-10-18 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN115768474A (zh) 2020-03-12 2023-03-07 里格尔药品股份有限公司 用于治疗covid-19相关病症的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5358652A (en) * 1992-10-26 1994-10-25 Ethyl Petroleum Additives, Limited Inhibiting hydrolytic degradation of hydrolyzable oleaginous fluids
EP1051181B1 (en) * 1997-12-31 2004-03-17 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US6238677B1 (en) * 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005526095A (ja) * 2002-03-20 2005-09-02 エラン ファーマ インターナショナル，リミティド 脆砕性の低い急速溶解投与剤型
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
ITMI20040498A1 (it) * 2004-03-16 2004-06-16 Solvay Solexis Spa Composizioni granulari
KR101278397B1 (ko) * 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
WO2012064377A1 (en) * 2010-03-29 2012-05-18 Chelsea Therapeutics, Inc. Antifolate compositions

Also Published As

Publication number Publication date
US8263122B2 (en) 2012-09-11
SI2217241T1 (sl) 2018-10-30
CO6280491A2 (es) 2011-05-20
RS57525B1 (sr) 2018-10-31
ES2672519T3 (es) 2018-06-14
NI201000078A (es) 2011-05-16
IL205204A (en) 2015-07-30
KR20100088622A (ko) 2010-08-09
IL205204A0 (en) 2010-12-30
CA2704474C (en) 2016-04-26
CY1122163T1 (el) 2020-07-31
US20120288543A1 (en) 2012-11-15
AU2008323938B2 (en) 2014-04-10
DK2217241T3 (en) 2018-08-06
CU23915B1 (es) 2013-07-31
EP2217241B1 (en) 2018-04-25
US20090123539A1 (en) 2009-05-14
US8372415B2 (en) 2013-02-12
HUE039193T2 (hu) 2018-12-28
CR11476A (es) 2010-08-27
TR201807879T4 (tr) 2018-06-21
UA102825C2 (ru) 2013-08-27
WO2009061909A3 (en) 2009-11-05
CN101998857A (zh) 2011-03-30
EA201070570A1 (ru) 2010-10-29
PL2217241T3 (pl) 2018-11-30
BRPI0820389A2 (pt) 2015-05-19
SG185961A1 (en) 2012-12-28
DOP2010000136A (es) 2010-09-30
AU2008323938A1 (en) 2009-05-14
KR20150129067A (ko) 2015-11-18
NZ585913A (en) 2012-06-29
JP2011503010A (ja) 2011-01-27
ECSP10010233A (es) 2010-07-30
CU20100089A7 (es) 2011-10-05
MY169761A (en) 2019-05-15
HRP20181174T1 (hr) 2018-09-21
WO2009061909A2 (en) 2009-05-14
JP5567487B2 (ja) 2014-08-06
EP2217241A2 (en) 2010-08-18
EA020210B1 (ru) 2014-09-30
US8652492B2 (en) 2014-02-18
US20130189359A1 (en) 2013-07-25
CA2704474A1 (en) 2009-05-14
LT2217241T (lt) 2018-09-10
MX2010004733A (es) 2010-06-25
KR101663838B1 (ko) 2016-10-07
PT2217241T (pt) 2018-06-11

Similar Documents

Publication Publication Date Title
HN2010000930A (es) Granulacion en humedo que utiliza un agente secuestrante de agua
CR11151A (es) Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-ciclopentilpropanitrilo
BR0205721A (pt) Formulações de oximorfona de liberação controlada
MX374396B (es) Rocio de fentanilo sublingual.
CL2014002511A1 (es) Compuestos derivados de 3-(imidazo[4,5-c]piridin-2-il)-indazol, inhibidores de una o mas proteinas en la ruta de señalizacion de wnt; composicion farmaceutica; y metodo de tratamiento de un trastorno o enfermedad en que esta implicada la señalizacion aberrante de wnt tal como cancer, osteoartritis y alzheimer, entre otras.
BRPI0716696A2 (pt) Sistema de aplicação para tratamento remoto de um animal
DOP2007000016A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina.
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
PA8759601A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
NL1034672A1 (nl) Medisch navigatiesysteem met gereedschap- en/of implantaatintegratie in fluoroscopische beeldprojecties en werkwijze voor het gebruik daarvan.
GT200900244A (es) Compuestos organicos y sus usos
MX2007009162A (es) Formas de dosis rsistente al alcohol.
UY30094A1 (es) Compuestos químicos
CR11430A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
MX2010001821A (es) Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
EP2206504A4 (en) STABLE IONIC BICARBONATE MEDICINES SOLUTION
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
FR2885034B1 (fr) Systeme de maintien en temperature, perioperatoire, d'un patient
ZA200703076B (en) Use of 2-substituted pyrimidines for combating nematode diseases of plants
UA100138C2 (ru) ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e АБО d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EP1879013A4 (en) METHOD FOR CONSTRUCTING SELF-VULGATED DRUG ORMULATIONS